METHODS: We conducted a Phase 1/2 pilot study of WHIM patients given plerixafor 0.02–0.08 mg/kg/d by continuous subcutaneous infusion for 1–2 years using an OmniPod insulin pump, and assessed compliance as well as effects on blood leukocyte counts, infections, chronic skin conditions and adverse events. The gene discussed is INS; the disease is infection.